¹ú¼ÊÓÐÊý²¡ÈÕعØ×¢Ó¤¶ù¾·ÂÎÖ¢£¬ÈÃÓÐÊý±»Íû¼û
¹ú¼ÊÓÐÊý²¡ÈÕ
¡°´ÉÍÞÍÞ¡±¡¢¡°½¥¶³ÈË¡±¡¢¡°ÔÂÁÁº¢×Ó¡±¡¢¡°µç±¦±¦¡±¡¡ÕâЩ¿É°®µÄÃû×Ö±³ºó£¬×Åʵ¶ÔÓ¦µÄÊÇÒ»¸ö¸öÓÐÊý²¡¡£¡°µç±¦±¦¡±¼´ÊǶԡ°Ó¤¶ù¾·ÂÎÖ¢¡±»¼¶ùµÄ³Æºô£¬ÓÉÓÚº¢×Ó·¢²¡Ê±¡°ò¥Êס±¡¢¡°Óµ±§¡±µÄÖ¢×´Ïñ´¥µçÒ»Ñù¶øµÃÃû¡£
½ñÌìÊÇ2ÔÂ28ÈÕ£¬Ò²Êǹú¼ÊÓÐÊý²¡ÈÕ¡£½ñÄê¹ú¼ÊÓÐÊý²¡ÈÕµÄÖ÷ÌâÊÇ¡°Share Your Colours¡±£¨·ÖÏíÄãµÄÉúÃüÉ«²Ê£©¡£
ÓÐÊý²¡²¢²»ÓÐÊý£¬ÔçÕïÔçÖÎÊÇÒªº¦
?¡°Ò©¡±ÓÐËùÒÀ£¬ÕÕÁÁ¡°Éú¶øÓÐÊý¡±µÄËûÃÇ
³ýÁËÄÑÒÔÈ·ÕÖÎÁÆÒ©ÎïµÄȱ·¦ÊÇÓÐÊý²¡»¼ÕßÖÎÁÆ·ÉÏÒ»´óÄÑÌ⡣ȫÇò7000¶àÖÖÓÐÊý²¡£¬ÓÐÒ©¿ÉÖεıÈÀýȱ·¦10%¡£ºÜÐÒÔË£¬ISÊÇÆäÖÐÖ®Ò»¡£
°±¼ºÏ©Ëá×÷ΪISÒ»ÏßÖÎÁÆÒ©ÎTSC°éISÊ×Ñ¡Ò©ÎÒѾÔÚÅ·ÖÞ¹ú¼ÒÉÏÊÐ30ÓàÄê4¡£Î¬¸ñ¶¨®(°±¼ºÏ©Ëá¿Ú·þÈÜÒºÓÃÉ¢)ÓÚ2022ÄêÔÚÖйúÕýʽÉÏÊУ¬ÊǺ£ÄÚÊ׸öÕýʽÉÏÊеݱ¼ºÏ©Ëá¡£ÆäδÔÚº£ÄÚÉÏÊÐ֮ǰ£¬º£ÄÚ¹ØÓÚÕâÒ»¼²²¡µÄÖÎÁÆ´¦ÔÚÉÙÒ©»òÎÞÒ©¿ÉÓõĽ׶Σ¬»¼¶ùÓÃÒ©ÐèҪרÃÅ´ÓÍâÑó´ú¹º£¬²¢ÇÒÓÐЩҩÎïÓÉÓÚÇå¾²ÎÊÌ⣬±£´æÓÃÒ©Òþ»¼£¬ÔçÇ°ÓÉÓÚÒßÇéÔµ¹ÊÔÓÉ£¬¸üÊÇʱ³£ÃæÁÙ¶ÏÒ©µÄΣº¦¡£
°±¼ºÏ©ËáµÄ×÷ÓûúÖÆÖ÷ÒªÊÇͨ¹ý²»¿ÉÄæµØÒÖÖÆGABAת°±Ã¸À´ÒÖÖÆGABAµÄÆÊÎö´úл£¬´Ó¶øÌá¸ß¾þÄÔÖÐGABAµÄŨ¶È¡£¸ÃÒ©¿ÉÒÔʵʱ¡¢ÓÐÓÿØÖÆ»¼¶ùñ²ðï¾·ÂΣ¬ÏÔןÄÉÆÔ¤ºó£¬Ìá¸ßIS»¼¶ùÉúÑÄÂʼ°ÉúÑÄÖÊÁ¿5-6¡£
2021Äê12Ô£¬¿Ê±AGµÇ¼Èë¿ÚÒ½Ò©ÓëÖйú¿¹ñ²ðïлá¸æ¿¢Õ½ÂÔÏàÖú£¬ÅäºÏ½¨Éè½á½ÚÐÔÓ²»¯¼°ñ²ðïÓÐÊý²¡×¨²¡Î¯Ô±»á£¬Íƶ¯º£ÄÚñ²ðïÓÐÊý²¡ÕïÁÆˮƽµÄÌáÉý£¬Èøü¶àµÄ»¼¶ùÄܽÓÊÜÔçÕï¡¢ÔçÖΡ£ÎªÇÐʵÓÐÓõØ×ÊÖú»¼¶ù¼ÒÍ¥¼õÇáÓÃÒ©¾¼Ã¼ç¸º£¬¿Ê±AGµÇ¼Èë¿ÚÒ½Ò©Æô¶¯»¼Õ߹ذ®¸£ÀûÍýÏ룬ЯÊÖÐÐҵר¼Ò´Ó¼²²¡ÕïÖΡ¢»¼ÕßÔ®Öú¡¢ÓÃÒ©°ü¹Ü¡¢¼ÒÍ¥¹Ø°®µÈ·½Ãæ½â¾ö²¿·ÖÓÐÊý²¡»¼Õß¼°Æä¼ÒÍ¥ÄÑÌâ¡£2022Ä꣬¿Ê±AGµÇ¼Èë¿ÚÒ½Ò©³ÉÔ±ÆóÒµÍò°îÒ½Ò©¾ÙÐÐÎåÊ®Óೡ»¼Õß¿ÆÆÕ¹«Òæ½²×ù£¬»¼Õ߹ذ®¸£ÀûÍýÏë¹²»Ý¼°1300Ãû»¼¶ù£¬¼«´óµÄ¼õÇáÁË»¼Õß¾¼Ã¼ç¸º£¬ÌáÉýÒ©Îï¿É¼°ÐÔÓëÒÀ´ÓÐÔ¡£
³ýÁËIS£¬ÉÐÓÐÒ»ÖÖÓÐÊýµÄ¼²²¡¶à·¢ÓÚ¶ùͯ¡ª¡ªÂýÐÔÈâÑ¿Ö×(chronic granulomatous disease,CGD)£¬ÊÇÖÂËÀÐÔÒÅ´«ÐÔ°×ϸ°û¹¦Ð§È±ÏÝ£¬¶àΪÐÔÁªÒþÐÔÒÅ´«¡£Ñ¬È¾ÊÇCGD»¼¶ù×î³£¼ûµÄÁÙ´²ÌåÏÖ£¬Ö÷Òª²¢·¢Ö¢¼ûÓÚÖÖÖÖÔàÆ÷»¯Å§ÐÔѬȾ£¬È縹ǻŧÖס¢¸ÎŧÖס¢ÄÔĤÑס¢ÑÏÖØÕß±¬·¢°ÜѪ֢¶øΣ¼°ÉúÃü¡£¶øÙ¤Âí×ÌÈÅËØ£¨IFN¦Ã£©µÄÓ¦ÓÃÄÜÓÐÓÿØÖÆCGD»¼ÕßµÄѬȾ²¢¸ÄÉÆÉúÑÄÇéÐΣ¬Îª»¼¶ùµÄ¼²²¡ÖÎÀí´øÀ´Ã÷È·µÄ»ñÒæ7¡¢8¡£¿Ê±AGµÇ¼Èë¿ÚÒ½Ò©³ÉÔ±ÆóÒµ×ÔÖ÷Ñз¢ÇÒÉú²úµÄIFN¦Ã£¬Îªº£ÄÚΨһIFN¦Ã£¬×ÝȻÿһ´ÎÆô¶¯Ò©ÎïÉú²úµÄ±¾Ç®´óÓÚÊÕÈ룬³Ð¼Ì¡°¹Ø°®ÉúÃü¡±µÄ¼ÛÖµ¹Û£¬¿Ê±AGµÇ¼Èë¿ÚÒ½Ò©ÈÔÒ»Á¬Éú²ú£¬ÖÂÁ¦Îª»¼¶ù¼ÒÍ¥´øÀ´ºã¾ÃÎÞ²¡ÉúÑĵÄÏ£Íû¡£
²»Òò¼²²¡ÓÐÊý¶øÖÃÈôØèÎÅ£¬²»ÒòȱҽÉÙÒ©¶øÖÃÖ®¶ÈÍ⣬ÓÐÊý²¡ÈºÌåÐèÒªÉç»á¸÷·½¹Ø×¢¡£ÌìÆø½¥Å¯£¬Ñô¹âÕýºÃ£¬ÈÃÎÒÃÇÒ»ÆðÆð¾¢£¬½«Ï£ÍûµÄ¹âÕÕ½øÿһ¸öÓÐÊý²¡»¼ÕߵļÒÍ¥£¬ÈÃÏ£Íû²»ÔÙÓÐÊý¡£
ÑÓÉìÔĶÁ£º¿Ê±AGµÇ¼Èë¿ÚÒ½Ò©ÓëÓÐÊý²¡
2019Äê9Ô£¬¿Ê±AGµÇ¼Èë¿ÚÒ½Ò©¼ÓÈëÖйúÓÐÊý²¡Í¬ÃË¡£¸ÃͬÃËÓɱ±¾©ÐºÍÒ½Ôº¡¢ÖйúÒ½Ò©Á¢ÒìÔö½ø»á¡¢ÖйúҽԺлáµÈǣͷÌᳫ£¬Ö¼ÔÚÍƶ¯Ò½Ñ§ÔÚÓÐÊý²¡Ñо¿·½ÃæÈ¡µÃÖØ´óÍ»ÆÆ£¬ÌáÉýÓÐÊý²¡·ÀÖÎÓë°ü¹Üˮƽ£¬Ôö½øÓÐÊý²¡ÁÙ´²¡¢¿ÆÑÐÓë¹Â¶ùÒ©¿ª·¢µÄÐͬÁ¢Òì¡£
2020Äê12ÔÂ23ÈÕ£¬ÔÚÉϺ£ÊÐÓÅÉúÓÅÓý¿ÆѧлᣨÉϺ£Êи¾Ó×±£½¡Ð»á£©¡¢ÉϺ£ÊÐÓÐÊý²¡·ÀÖλù½ð»á¡¢ÉϺ£¸ßˮƽµØ·½¸ßУÖصãÁ¢ÒìÍŶӣ¨¶ùͯ¿µ½¡Î¬»¤ÓëÔö½ø£©ÏîĿר¼Ò×éµÄÖ¸µ¼Ï£¬¿Ê±AGµÇ¼Èë¿ÚҽҩЯÊÖÉϺ£¿Ê±AGµÇ¼Èë¿Ú¹«Òæ»ù½ð»á¡¢¸´µ©´óѧÁ¥Êô¶ù¿ÆÒ½Ôº£¬ÅäºÏÆô¶¯¡°ÐÇÑ¿¡±¶ùͯÓÐÊý²¡¹Ø°®×¨Ïî»ù½ð£¬ÖÂÁ¦ÓÚΪ¸ü¶à¶ùͯÓÐÊý²¡»¼ÕßÌṩȫÉúÃüÖÜÆÚµÄÕչ˺͹ذ®¡£
2022Äê1Ô£¬ÓɿʱAGµÇ¼Èë¿ÚÒ½Ò©³ÉÔ±ÆóÒµÍò°îÒ½Ò©Òý½øµÄÖйúÊ׸öÈë¿Ú°±¼ºÏ©ËáÉ¢¼Á¡ª¡ªÎ¬¸ñ¶¨®ÉÏÊУ¬Ö÷ÒªÓÃÓÚ1¸öÔµ½2ËêÓ¤¶ùµÄÓ¤¶ù¾·ÂÎÖ¢£¬¸ÃÒ©¿ÉÒÔʵʱ¡¢ÓÐÓÿØÖÆ»¼¶ùñ²ðï¾·ÂΣ¬ÏÔןÄÉÆÔ¤ºó£¬Ìá¸ßIS»¼¶ùÉúÑÄÂʼ°ÉúÑÄÖÊÁ¿¡£
¿Ê±AGµÇ¼Èë¿ÚÒ½Ò©¼¯ÍÅÆð¾¢ÏìÓ¦¹ú¼Ò´óÁ¦ÌᳫÁÙ´²¼±ÐèºÍÓÐÊý²¡Ò©ÎïµÄ×¢²áÑз¢£¬ÏÖÔÚͨ¹ýÔÊÐíÒý½øµÄģʽ£¬ÔÚÓ¤¶ù¾·ÂÎÖ¢¡¢ÌØ·¢ÐÔ·ÎÏËά»¯¡¢·Î¶¯Âö¸ßѹµÈ˳Ӧ֢£¨²Î¿¼¹ú¼ÒÎÀÉú¿µ½¡Î¯Ô±»áÐû²¼µÄ¡¶µÚÒ»ÅúÓÐÊý²¡Ä¿Â¼¡·£©ÓµÓÐÓÐÊý²¡Ò©ÎÖÂÁ¦ÓÚÌá¸ßÁ¢ÒìÖÎÁÆÒ©ÎïÔÚÓÐÊý²¡»¼ÕßÖеĿɼ°ÐÔ¡£
²Î¿¼ÎÄÏ×£º
1¡¢¹ù»¢, Ö£àþ. Ó¤¶ù¾·Âι²Ê¶½â¶Á[J]. ÊÊÓöù¿ÆÁÙ´²ÔÓÖ¾, 2011, 26(12):978-980.
2¡¢Curatolo P, et al. Eur J Paediatr Neurol.?2018 Sep;22(5) 738-748.
3¡¢Peron A, et al. Am J Med Genet C Semin Med Genet.?2018?Sep;178(3):281-290.
4¡¢Ben-Menachem E.Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol ScandSuppl. 2011(192): 5¨C15, doi: 10.1111/j.1600-0404.2011.01596.x, indexed inPubmed: 22061176.
5¡¢°±¼ºÏ©Ëá˵Ã÷Êé
6¡¢Jackson MC,Jafarpour S, Klehm J, et al. Effect of vigabatrin on seizure control and safetyprofile in different subgroups of children with epilepsy. Epilepsia. 2017;58(9): 1575¨C1585.
7¡¢Ð¡¶ùÖظ´ÑÏÖØѬȾ£ºÌá·À¡°ÂýÐÔÈâÑ¿Öײ¡£¬¡¶¹«¹²Ò½Ñ§¡·? 2017ÄêµÚ5ÆÚ24-24
8¡¢çÑÒ«·¼.С¶ùÂýÐÔÈâÑ¿Öײ¡:£® ¡¶ ÍâÑóҽѧ.ÁÙ´²·ÅÉäѧ·Ö²á ¡· £¬ 1990